PubMed · 2013 · 14 citations · 54 references
Open access
MedicineOncologySurgeryBreast OncologyMetastasisSurgical OncologyBreast Cancer SurgeryBreast Cancer-related LymphedemaBreast SurgeryBreast-conserving TherapyLymph Node MetastasisSentinel Lymph Node BiopsyAxillary Lymph Node Dissection-associated LymphedemaAxillary Lymph Node Involvement AssessmentAxillary Lymph Node MetastasisAxillary Lymph Node SurgeryLocal Tumor RecurrenceLymph Node MetastasesRisk-benefit Decision MakingSentinel Lymph Node Metastasis
AIM: Breast cancer-related lymphoedema (BCRL) is a disabling complication developing after breast cancer treatment in a proportion of patients. Its impact on quality of life becomes more substantial as survival after breast cancer diagnosis increases. The incidence of BCRL following breast cancer treatment varies due to a lack of -uniform definition and measurement criteria. This review aims to determine the prevalence of BCRL following axillary lymph node dissection (ALND) as a benchmark to be used in a risk-benefit medical decision whether to proceed with ALND or not. The risk of leaving unresected non-sentinel metastatic lymph nodes with a presumed inherent risk of local recurrence will be balanced against the risk of BCRL following a potentially unnecessary ALND. METHODS: Pubmed and Embase databases were searched for all publications on BCRL in order to estimate its -incidence and to decide on the most appropriate measurement method to use in clinical practice. RESULTS: 51 articles were identified on BCRL incidence and measurement technique. Most studies measured BCRL based on differences in arm circumference (n = 18) or by self-reported symptoms (n = 18). The weighted average of BCRL incidence following ALND measured by self-report and circumference method was 28% and 16%, respectively. CONCLUSION: The importance of ALND and irradiation as part of the treatment of operable breast carcinoma is well established, but its morbidity is less well documented. We argue self-report as the most appropriate method to -establish a diagnosis of BCRL. Therefore a 28% risk of finding non-sentinel lymph node metastases in a completion ALND will be regarded as the cut-off in a medical decision to proceed with ALND.
54
David N. Krag, Stewart Anderson, Thomas B. Julian et al. · The Lancet Oncology · 2007 · 1.1K citations
Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis
Jeanne A. Petrek, Ruby T. Senie, Margaret Peters et al. · Cancer · 2001 · 683 citations · Full text